Website designed by: Vanmala VONGKINGKEO
Icons made by Twitter from www.flaticon.com
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821508. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
-CARDIATEAM-
0
Years
2019 – 2024
0
Partners
0
Countries
0
Million Euros funding
A rapidly evolving epidemic in Type 2 Diabetes (T2DM) is afflicting all ages, sexes and socioeconomic classes which includes serious comorbidities such as heart diseases. While ischaemic heart disease represents the major cause of death of T2DM patients, heart failure (80% of Heart Failure with preserved Ejection Fraction) is the second most common cardiovascular disease in T2DM patients.
The aim of CARDIATEAM is to determine whether T2DM represents a central mechanism contributing to the pathogenesis and progression of a specific cardiomyopathy, called “diabetic cardiomyopathy” (DCM), assessing whether DCM is unique and distinct from the other forms of heart failure.
OUR OBJECTIVES
Assess the uniqueness of Diabetic Cardiomyopathy
Provide access to cohorts within CARDIATEAM consortium for
- enrolment into a new one with deeply phenotyped patients with broad spectrum of cardiometabolic disorders
- access to existing published data for retrospective epidemiological meta-analyses.
Explore by unbiased statistical clustering analysis the specific contribution of Type 2 Diabetes to the development of diabetic cardiomyopathy.
Explore the role of confounding factors that include ageing process and metabolic exposome in inducing diabetic cardiomyopathy.
Understand the physiological pathways responsible for establishment and progression of diabetic cardiomyopathy by translating bedside phenotypic data to bench preclinical models of diabetic cardiomyopathy.
Use diabetic cardiomyopathy as a representative comorbidity for the paradigm of Heart Failure and a targetable mechanism for proof-of-concept studies
Explore the role of existing and newly identified biomarkers for risk stratification of Type 2 Diabetes patients and their potential application for personalised preventive and therapeutic strategies.
HOW WILL WE ACHIVE THEM?
- Interrogation of the available key longitudinal cohorts and new prospectively recruited CARDIATEAM cohorts to better understand the progression of diabetic cardiomyopathy to Heart Failure
- Combination of deep clinical phenotyping with state -of-the-art big-data processing techniques
- Identification of new imaging and molecular biomarkers
- Prototyping of preclinical experimental models and tailor system-biology methods to identify innovative therapeutic targets
WHO IS INVOLVED IN THE CARDIATEAM PROJECT?
CONTACT US
Kristina FIEDLER – EU project manager
kristina.fiedler(@)inserm-transfert.fr
Dr. Anne PIZARD – Coordinator contact INSERM
anne.pizard(@) inserm.fr
What's new on our LinkedIn page?
Click on the icon below to have access to our latest posts!
Acknowledgement
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821508. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
See more on Cordis portal.
The contents of this website and the view expressed in the news and publications are the sole responsibility of the authors and under no circumstances can be regarded as reflecting the position of the European Union or the JU.
Read our privacy policy and legal notice.
